Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva gets approval for generic Actonel
Teva is currently in patent litigation concerning this product in the US district court for the District of Delaware. In connection with the pending patent litigation, Teva has
Teva is currently in patent litigation concerning this product in the US district court for the District of Delaware. In connection with the pending patent litigation, Teva has
The trial, which is aimed at determining the pharmacokinetics of two doses of Zenvia (dextromethorphan/quinidine) in the treatment of pseudobulbar affect (PBA) in patients with amyotrophic lateral sclerosis
A 12-week, placebo controlled, double blind, randomised Phase IIa study was designed to explore whether clinically relevant LDL-cholesterol lowering can be achieved without adversely affecting the heart, bone,
After receiving technical clearance of the electronic common technical document from the FDA, the regulatory review period will begin, the German drug discovery company said. Jens Schneider-Mergener, CEO
Akesis will initiate the trial after FDA approval. The trial will be performed by dgd Research of San Antonio and will be designed to measure efficacy (using the
In a Phase III, multi-center, double-blind trial, 257 patients with diabetic foot infections without concomitant osteomyelitis were randomized to receive either 500mg of ceftobiprole administered intravenously every eight
Data for HE3286 has showed significant benefit in the wistar rat model of dinitrobenzene sulfonic acid (DNBS) induced colitis, a preclinical model widely used in industry and academia
The program used RNAi therapeutics directed to the disease target proprotein convertase subtilisn/kexin type 9. The data shows that in vivo systemic administration of an RNAi therapeutic in
The acquisition will be complementary to Cyclacel’s oncology/hematology products in development, according to the company, and is part of Cyclacel’s strategy to build a diversified biopharmaceutical business. Cyclacel’s
The Revimmune multiple sclerosis (MS) study will enroll subjects in a one-year study comparing baseline disability to disability at month 12 with an interim data analysis. After consultation